1. Home
  2. THG vs GKOS Comparison

THG vs GKOS Comparison

Compare THG & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • THG
  • GKOS
  • Stock Information
  • Founded
  • THG 1852
  • GKOS 1998
  • Country
  • THG United States
  • GKOS United States
  • Employees
  • THG N/A
  • GKOS N/A
  • Industry
  • THG Property-Casualty Insurers
  • GKOS Medical/Dental Instruments
  • Sector
  • THG Finance
  • GKOS Health Care
  • Exchange
  • THG Nasdaq
  • GKOS Nasdaq
  • Market Cap
  • THG 5.8B
  • GKOS 5.1B
  • IPO Year
  • THG 1995
  • GKOS 2015
  • Fundamental
  • Price
  • THG $166.48
  • GKOS $90.36
  • Analyst Decision
  • THG Buy
  • GKOS Strong Buy
  • Analyst Count
  • THG 9
  • GKOS 13
  • Target Price
  • THG $179.00
  • GKOS $135.15
  • AVG Volume (30 Days)
  • THG 266.8K
  • GKOS 1.1M
  • Earning Date
  • THG 04-30-2025
  • GKOS 04-30-2025
  • Dividend Yield
  • THG 2.16%
  • GKOS N/A
  • EPS Growth
  • THG 167.70
  • GKOS N/A
  • EPS
  • THG 12.02
  • GKOS N/A
  • Revenue
  • THG $6,289,500,000.00
  • GKOS $404,523,000.00
  • Revenue This Year
  • THG $5.97
  • GKOS $27.84
  • Revenue Next Year
  • THG $5.93
  • GKOS $27.88
  • P/E Ratio
  • THG $13.88
  • GKOS N/A
  • Revenue Growth
  • THG 3.09
  • GKOS 23.92
  • 52 Week Low
  • THG $119.66
  • GKOS $77.10
  • 52 Week High
  • THG $176.16
  • GKOS $163.71
  • Technical
  • Relative Strength Index (RSI)
  • THG 53.84
  • GKOS 47.66
  • Support Level
  • THG $165.49
  • GKOS $84.26
  • Resistance Level
  • THG $171.09
  • GKOS $92.27
  • Average True Range (ATR)
  • THG 3.59
  • GKOS 3.86
  • MACD
  • THG 0.53
  • GKOS 0.66
  • Stochastic Oscillator
  • THG 63.24
  • GKOS 65.16

About THG Hanover Insurance Group Inc

The Hanover Insurance Group Inc is a holding company whose primary business is offering property and casualty insurance products and services. The company markets itself through independent agents and brokers in the United States while conducting business internationally through a wholly owned subsidiary, Chaucer Holdings Limited, domiciled in the United Kingdom. The company conducts business operations through three operating segments: Commercial Lines, Personal Lines, and Other. The company operates an investment portfolio that is exposed to fixed-income securities.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: